Elcella: Critical analysis and review of the ’’Natural GLP-1 Alternative’’

Jump to: What Elcella claims to do | Ingredient analysis | The science vs. marketing reality | Cost and value assessment | UK considerations | Evidence-based alternatives | Take home message

There’s no substantial evidence that Elcella effectively stimulates GLP-1 production enough to deliver meaningful weight loss comparable to prescription medications like Mounjaro or Wegovy.

While founded by legitimate researchers from Queen Mary University of London, Elcella’s weight loss claims (an average of 6kg over 12 weeks) are based on unpublished research that hasn’t undergone peer review.¹

The only published study tested a single dose in 20 volunteers, showing a 13% reduction in food intake at just one meal.² Media coverage has made comparisons to prescription medications, with some outlets referencing Elcella as a “natural” alternative to Ozempic.³

UK data shows approximately 28% of adults are living with obesity, creating significant demand for accessible weight management solutions, especially given NHS waiting times for GLP-1 medications.⁹

At £595 for a 12-week programme (potentially £2,380 annually at the starting dose), Elcella’s initial cost is comparable to prescription GLP-1 weight-loss medications while offering less robust published evidence for effectiveness.¹

What Elcella claims to do

Elcella markets itself as a “natural alternative” to weight loss medications like Ozempic and Wegovy, claiming to help the body release its own appetite-reducing hormones without side effects.^1,11

The company positions its product as backed by a decade of research from Queen Mary University of London, developed by neurogastroenterology experts Dr. Madusha Peiris and Dr. Rubina Aktar.¹

According to the Elcella website, their capsules work by:

• Stimulating the natural release of GLP-1 and PYY hormones in the colon¹
• Using a pH-based colonic-release coating system designed to deliver active components directly to the colon¹²
• Targeting specific receptors (GPR84 and FFAR4) on L-cells to boost hormone production²

The marketing makes several bold claims:

• 94% improvement in appetite control over 12 weeks¹
• 6kg average weight loss in 12 weeks¹
• 7cm average waistline reduction¹
• Increases in GLP-1 and PYY hormone levels by 2.5 times¹¹
• Zero side effects observed in three clinical trials¹

Users are instructed to take 8 capsules daily (4 capsules, twice daily) 3 hours before lunch and dinner, with Elcella indicating that this dosage may taper over time.¹

The regimen requires consistency over at least 12 weeks, with the founders suggesting it may become “a staple in your daily wellness routine”.¹

What’s immediately concerning is that while the marketing refers to multiple clinical trials showing significant weight loss, only one study has been published in a peer-reviewed journal. It tested a single dose, not a 12-week programme.²

Ingredient analysis

Elcella contains three oils in a plant-based, pH-based colonic-release capsule:¹

• Virgin cold-pressed organic linseed oil (flaxseed oil)
• Coconut oil
• MCT oil (medium-chain triglycerides)

According to Elcella, their formulation utilizes specific medium- and long-chain fatty acids extracted from these oils for their biochemical composition and targeted role in the gut-brain axis, rather than using the oils themselves for standalone appetite effects.¹

However, without published formulation details, the available evidence for these individual components shows:

The fundamental issue is ingredient transparency. Elcella doesn’t disclose the exact amount of each fatty acid per capsule, making it difficult to evaluate the therapeutic concentrations of these extracted compounds.¹

A 2022 systematic review found that while whole flaxseed (≥30g daily for ≥12 weeks) showed modest benefits in overweight participants, flaxseed oil alone didn’t significantly improve body composition.³

Elcella states that their colonic-release capsules bypass stomach dissolution, potentially avoiding the GI distress sometimes associated with MCT oil consumption. Without published dissolution testing data, however, it’s difficult to verify the consistency of this delivery system across varied gut conditions.⁸

The science vs. marketing reality

The primary published research supporting Elcella is a 2022 study in the journal Gut titled “Decoy bypass for appetite suppression in obese adults: role of synergistic nutrient-sensing receptors GPR84 and FFAR4 on colonic endocrine cells”.²

This peer-reviewed study provides the foundation for Elcella’s claims, but the actual results are far more modest than the marketing suggests:

What the published study actually tested:

• Sample size: 20 obese volunteers (BMI 30-40)²
• Study design: Single-day acute study
• Primary finding: 13% reduction in food intake at a single meal compared to placebo²
• Secondary findings: Increased PYY and GLP-1 levels in blood²

What Elcella marketing claims:

• 6kg average weight loss over 12 weeks¹
• 7cm average waistline reduction¹
• 94% improvement in appetite control¹

Media coverage has compared Elcella’s effects to those of prescription GLP-1 medications, with some outlets using phrases like “natural weight loss drug as effective as Ozempic.”

While Elcella indicates they haven’t made this specific claim in their marketing materials, such comparisons in media coverage may create expectations of similar efficacy. Brands are still responsible for clarifying publicly when such comparisons are overstated or unsupported.³

For comparison, prescription GLP-1 medications have published results from large clinical trials:

• Wegovy (semaglutide 2.4 mg): 14.9% average weight loss at 68 weeks⁶
• Mounjaro (tirzepatide 15 mg): 20.9% average weight loss at 72 weeks⁷

These medications directly activate GLP-1 receptors and avoid the breakdown that the natural hormone undergoes.¹³

In contrast, Elcella attempts to stimulate natural production through oils delivered to the colon, a fundamentally different approach.¹

A 13% reduction in calorie intake from a single meal doesn’t translate linearly to sustained weight loss. The body compensates through increased hunger at subsequent meals, reduced activity, and metabolic adaptation (energy expenditure).¹³

While Dr Peiris and Dr Aktar are legitimate researchers with published work in gut physiology, the specific claims about Elcella’s long-term effectiveness are based on unpublished trials that haven’t undergone peer review.

The company indicates some data may be withheld due to patent filing processes. This is common during product development, but it weighs against transparency for consumers.¹

Cost and value assessment

Elcella is marketed as more affordable than GLP-1 medications. Let’s examine the costs:

Elcella Pricing:

• 12-week plan: £595 (one-time payment) or 4 instalments of £148.75¹
• Per month (initial): £198.33
• Initial daily dosage: 8 capsules daily

Elcella indicates that dosing tapers over time, which would reduce the long-term cost below our initial calculation based on the 12-week plan pricing. However, specific tapering protocols and associated cost reductions aren’t detailed on their public website.¹

UK Private GLP-1 Medication Costs (approximate):

• Wegovy 2.4 mg (highest dose): £249/month = £2,988/year
• Wegovy 1 mg (lower dose): £199/month = £2,388/year
• Mounjaro 15 mg (highest dose): £349/month = £4,188/year
• Mounjaro 5 mg (lower dose): £249/month = £2,988/year
• Saxenda: £150/month = £1,800/year

Based on the initial 8-capsule dosage, Elcella’s cost would be comparable to that of lower-dose GLP-1 medications, although potentially lower due to their tapering protocol.

Cost-Benefit Comparison:

UK regulatory and safety considerations

MHRA and FSA oversight

Elcella is classified as a “food supplement, not a medicine”, which means:¹

• No pre-market approval required from the MHRA (Medicines and Healthcare products Regulatory Agency)
• Food Standards Agency (FSA) oversight focused on safety, not efficacy¹⁴
• Can make structure/function claims but not disease treatment claims

This classification enables Elcella to market appetite and weight management benefits while avoiding the rigorous clinical trial requirements associated with medications.¹⁴

Advertising standards

The UK Advertising Standards Authority (ASA) has clear guidelines about weight loss claims for supplements:¹⁵

• Claims must be backed by robust evidence
• Testimonials alone are insufficient
• Comparisons to medications require substantiation
• “Clinically proven” claims need published clinical evidence

Elcella’s marketing includes several elements that could potentially raise concerns:

• References to specific weight loss amounts without published supporting studies¹
• Use of “validated in vivo studies” terminology without accessible peer-reviewed publications¹²

Safety considerations

While the ingredients in Elcella appear generally safe for most adults, several considerations warrant attention:

Colonic-release system: Elcella uses a pH-based colonic-release coating system designed to target delivery to the colon. However, the manufacturing consistency, dissolution testing data, and consistency testing for these capsules haven’t been published in peer-reviewed literature.⁸

Ingredient transparency: The company doesn’t disclose the exact amount of each active compound per capsule, making it difficult to assess the total daily caloric content and other nutritional factors.¹

Individual variability: Gastrointestinal transit time varies significantly between individuals (6-70+ hours). Factors affecting transit include diet, hydration, medications, gut microbiome composition, and underlying conditions.⁸ This variability could potentially impact the consistency of delivery to the colon across different users.

Evidence-based alternatives

For lower hunger:

High-protein breakfast:

• Eggs, Greek yoghurt, or protein-rich smoothies provide longer-lasting impact on lowering hunger while providing a range of essential nutrients
• Far more affordable and accessible than supplements

Fibre-rich meals:

• Beans, lentils, vegetables, and whole grains offer better satiety benefits than supplements
• Whole flaxseeds (not just the oil) provide both soluble and insoluble fibre that supports satiety³
• Milled flaxseeds can be purchased from most supermarkets for between £3-£7

Adequate sleep and stress management:

• Poor sleep significantly increases hunger hormones and cravings
• Stress reduction techniques help manage emotional eating

For sustainable weight management:

NHS weight management programmes:

• Free, evidence-based support focusing on sustainable habit changes
• Access through GP referral

Structured behaviour change programmes:

• Services like Second Nature combine behavioural psychology with nutrition support
• Second Nature has shown average weight losses of 6.2kg at 12 months in NHS trials¹⁰
• For medication programmes, Second Nature offers semaglutide support with published outcomes showing 18.1kg average weight loss at 12 months¹⁰

Prescription GLP-1 medications:

• For those meeting clinical criteria, medications like Mounjaro have extensive clinical evidence^6,7
• Prescribed through NHS or private healthcare with medical supervision

Natural GLP-1 supporters (with better evidence):

Instead of expensive supplements with limited evidence, consider these evidence-based approaches:

• A diet based on whole foods: Eating a diet that contains a wide variety of nutrients that’s rich in fat, protein, complex carbohydrates, and fibre will support naturally high levels of GLP-1 and other hunger-lowering hormones¹³
• Whole flaxseeds: 2-3 tablespoons daily provides both fibre and ALA (the active compound in flaxseed oil)³
• Fermented foods: Yoghurt, kefir, and kimchi support a healthy gut microbiome that enhances GLP-1 production
• Protein-rich foods: Lean meats, fish, legumes, and dairy naturally stimulate GLP-1 release
• Green tea: Contains compounds that may modestly support metabolic health

These evidence-based approaches address the fundamental behaviours and patterns that influence weight and metabolism, rather than promising quick fixes through supplements.

Take home message

Elcella represents an interesting intersection of legitimate scientific research and aggressive marketing.

The founders are credible researchers who have published work on nutrient-sensing mechanisms in the gut.

However, the gap between their published research (a 13% reduction in intake at a single meal) and marketing claims (an average weight loss of 6 kg over 12 weeks) is substantial.^1,2 While the company indicates that additional data exists but may be withheld due to patent filing processes, independent scientific evaluation requires published, peer-reviewed evidence.

The supplement contains extracted fatty acids from three oils (flaxseed oil, coconut oil, and MCT oil) delivered via a pH-based colonic-release system, but the specific formulation has not been independently tested in published clinical trials.^3,4,5

For those seeking evidence-based weight management solutions, consider:

1. Speaking with your GP about NHS weight management options
2. Exploring structured programmes with published outcomes like Second Nature¹⁰
3. Incorporating whole foods known to support satiety (protein, fibre, whole flaxseeds)
4. Discussing medication options with healthcare professionals if appropriate

Until Elcella publishes its 12-week weight loss trials in peer-reviewed journals with full methodology, results, and statistical analysis, claims about average weight loss should be viewed with appropriate scepticism.

Remember: If an approach to weight management sounds too good to be true – particularly one claiming medication-like results without the side effects – it usually is.

References

1. Elcella. The Elcella Method. [Internet]. 2025 [cited 2025 Nov 3].
2. Aktar R, Peiris M, Amin L, Huang C, Pontis J, Tan V, et al. Decoy bypass for appetite suppression in obese adults: role of synergistic nutrient sensing receptors GPR84 and FFAR4 on colonic endocrine cells. Gut. 2022;71(5):928-941.
3. Mohammadi-Sartang M, Mazloom Z, Raeisi-Dehkordi H, Barati-Boldaji R, Bellissimo N, Totosy de Zepetnek JO. The effect of flaxseed supplementation on body weight and body composition: a systematic review and meta-analysis of 45 randomized placebo-controlled trials. Obes Rev. 2017;18(9):1096-1107.
4. St-Onge MP, Mayrsohn B, O’Keeffe M, Kissileff HR, Choudhury AR, Laferrère B. Impact of medium and long chain triglycerides consumption on appetite and food intake in overweight men. Eur J Clin Nutr. 2014;68(10):1134-1140.
5. Maher T, Kinsella R, Clegg ME. The effect of coconut oil and MCT on satiety and food intake. Proc Nutr Soc. 2017;76(OCE1). doi:10.1017/S0029665117000027
6. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
7. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
8. Nandhra GK, Chaichanavichkij P, Birch M, Scott SM. Gastrointestinal Transit Times in Health as Determined Using Ingestible Capsule Systems: A Systematic Review. J Clin Med. 2023 Aug 13;12(16):5272. doi: 10.3390/jcm12165272. PMID: 37629314.
9. Public Health England. Obesity profile: short statistical commentary May 2025. GOV.UK. 2025.
10. Richards R, Lunt W, Whitman M, Spaltro G, Hall R. Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study. JMIR Form Res. 2025 Sep 12;9:e81912. doi: 10.2196/81912. PMID: 40838489; PMCID: PMC12475876.
11. Elcella. Meet the Scientists. [Internet]. 2025 [cited 2025 Nov 3].
12. Elcella. How It Works. [Internet]. 2025 [cited 2025 Nov 3].
13. Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024 Sep 18;9(1):234. doi: 10.1038/s41392-024-01632-7.
14. Food Standards Agency. Food Supplements Guidance. GOV.UK. 2024.
15. Advertising Standards Authority. Weight loss: ASA guidance on making weight loss claims. ASA. 2023.